Yantai Zhenghai Bio-Tech Co. Ltd. Class A

Yantai Zhenghai Bio-Tech Co. Ltd. Class A

SSZSE:300653
13.45
CNY
-0.16
(-1.18%)
0.35EPS
45.05P/E
2.87BMarket Cap
Apr 06Next Earn

Total Valuation

CNY

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A carries a market capitalization of 2.87B, placing it among publicly traded companies globally. Its enterprise value stands at 2.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.87B
Enterprise Value2.24B

Important Dates

Yantai Zhenghai Bio-Tech Co. Ltd. Class A's next confirmed earnings release is scheduled for April 6, 2027.

Earnings Date4/6/2027

Share Statistics

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A has 180.00M shares outstanding.

Shares Outstanding180.00M

Valuation Ratios

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 45.05. The price-to-sales ratio is 8.94, and the price-to-book ratio stands at 3.23.

PE Ratio45.05
PS Ratio8.94
PB Ratio3.23
P/TBV Ratio3.35

Enterprise Valuation

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A trades at an EV/EBITDA multiple of 31.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.24B versus a market cap of 2.87B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.00
EV / EBITDA31.52
EV / EBIT31.52

Financial Position

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A maintains a current ratio of 9.44, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

Current Ratio9.44
Quick Ratio8.10

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A posted a return on equity (ROE) of 7.28, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.28, useful for judging operating efficiency across full business cycles. The company generates approximately 843,230.64 in revenue per employee across its workforce of 379.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.48 indicates how many times Yantai Zhenghai Bio-Tech Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)7.28
Return on Assets (ROA)6.62
Return on Invested Capital (ROIC)7.41
Return on Capital Employed (ROCE)7.28
Revenue Per Employee843,230.64
Employee Count379.00
Inventory Turnover1.48

Taxes

CNY

Over the twelve months ended September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A recorded 5.93M in income tax expense. That works out to an effective tax rate of 8.55, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 69.37M, leaving 63.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax5.93M
Effective Tax Rate8.55

Stock Price Statistics

CNY

As of the close on November 17, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A's stock has declined approximately 35.68% over the past 52 weeks. The 50-day moving average sits at 14.81, while the 200-day moving average is 16.78.

52-Week Price Change-35.68%
50-Day Moving Average14.81
200-Day Moving Average16.78

Income Statement

CNY

Over the twelve months ended September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A generated 319.58M in revenue and converted that into 63.44M in net income, yielding earnings per share of 0.35. EBITDA reached 71.02M, while operating income came in at 56.33M.

Revenue319.58M
Gross Profit268.62M
Operating Income56.33M
Pretax Income69.37M
Net Income63.44M
EBITDA71.02M
EBIT71.02M
Earnings Per Share (EPS)0.35

Balance Sheet

CNY

These figures are as of September 30, 2026. Total book value stands at 888.17M, with working capital of 657.37M providing operational flexibility.

Cash & Cash Equivalents630.70M
Net Debt-55.70M
Equity (Book Value)888.17M
Book Value Per Share4.93
Working Capital657.37M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-15.60M

Margins

Over the twelve months ended September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A posted a gross margin of 84.05, reflecting its pricing power and cost economics. The operating margin of 17.63 and net profit margin of 19.85 provide insight into operational efficiency.

Gross Margin84.05
Operating Margin17.63
Pretax Margin21.71
Profit Margin19.85
EBITDA Margin22.22

Stock Splits

Yantai Zhenghai Bio-Tech Co. Ltd. Class A's most recent stock split took place on May 19, 2022 with a 2:3 split ratio.

Last Split Date5/19/2022
Split Ratio2:3

Scores

As of September 30, 2026, Yantai Zhenghai Bio-Tech Co. Ltd. Class A has an Altman Z-Score of 21.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score21.63